Sino Biopharmaceutical Valuation Multiples

Sino Biopharmaceutical Overview

About Sino Biopharmaceutical

Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

Founded

2000

HQ

Employees

24.4K

Website

sinobiopharm.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $5B

EBITDA: $1B

EV

$13B

Valuation Multiples

Multiples.vc

Start free trial

Sino Biopharmaceutical Financials

Sino Biopharmaceutical reported last 12-month revenue of $5B and EBITDA of $1B.

In the same LTM period, Sino Biopharmaceutical generated $4B in gross profit, $1B in EBITDA, and $647M in net income.

Sino Biopharmaceutical P&L

In the most recent fiscal year, Sino Biopharmaceutical reported revenue of $4B and EBITDA of $1B.

Sino Biopharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX

Sino Biopharmaceutical Stock Performance

Sino Biopharmaceutical has current market cap of $14B, and enterprise value of $13B.

Sino Biopharmaceutical's stock price is $0.77.

Sino Biopharmaceutical Valuation Multiples

Sino Biopharmaceutical trades at 2.7x EV/Revenue multiple, and 10.3x EV/EBITDA.

Sino Biopharmaceutical Financial Valuation Multiples

As of April 18, 2026, Sino Biopharmaceutical has market cap of $14B and EV of $13B.

Equity research analysts estimate Sino Biopharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sino Biopharmaceutical has a P/E ratio of 21.2x.

Sino Biopharmaceutical Margins & Growth Rates

Sino Biopharmaceutical's revenue in the last 12 month grew by 12%.

Sino Biopharmaceutical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Sino Biopharmaceutical's rule of 40 is 42% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sino Biopharmaceutical's rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Sino Biopharmaceutical Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Sino Biopharmaceutical M&A Activity

Sino Biopharmaceutical acquired XXX companies to date.

Last acquisition by Sino Biopharmaceutical was on XXXXXXXX, XXXXX. Sino Biopharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Sino Biopharmaceutical Investment Activity

Sino Biopharmaceutical invested in XXX companies to date.

Sino Biopharmaceutical made its latest investment on XXXXXXXX, XXXXX. Sino Biopharmaceutical invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).